Is Bluebird Bio Stock a Buy?
https://www.fool.com/investing/2024/05/16/is-bluebird-bio-stock-a-buy/?source=iedfolrf0000001
May 16, 2024 - It won't be easy for the company to bounce back.
0
How Much Upside is Left in Zura Bio Limited (ZURA)? Wall Street Analysts Think 248.84%
https://www.zacks.com/stock/news/2274181/how-much-upside-is-left-in-zura-bio-limited-zura-wall-street-analysts-think-248-84?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2274181
May 15, 2024 - The average of price targets set by Wall Street analysts indicates a potential upside of 248.8% in Zura Bio Limited (ZURA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
0
Zura Bio Limited (ZURA) Upgraded to Buy: Here's What You Should Know
https://www.zacks.com/stock/news/2273666/zura-bio-limited-zura-upgraded-to-buy-here-s-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2273666
May 14, 2024 - Zura Bio Limited (ZURA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
0
Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2273125/generation-bio-co-gbio-reports-q1-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2273125
May 13, 2024 - Generation Bio (GBIO) delivered earnings and revenue surprises of -211.11% and 34.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
0
INmune Bio, Inc. (INMB) Q1 2024 Earnings Call Transcript
https://seekingalpha.com/article/4692437-inmune-bio-inc-inmb-q1-2024-earnings-call-transcript?source=feed_sector_transcripts
May 11, 2024 - INmune Bio, Inc. (NASDAQ:NASDAQ:INMB) Q1 2024 Results Conference Call May 9, 2024 4:30 PM ETCompany ParticipantsDavid Moss - Chief Financial OfficerDr.
0
Tevogen Bio secures up to $50M in financing
https://seekingalpha.com/news/4104888-tevogen-bio-secures-up-to-50m-in-financing?source=feed_sector_healthcare
May 10, 2024 - Tevogen Bio secures up to $50M financing for research and development efforts, focused on clinical development of TVGN 489 from ExacTcell platform.
0
GRI Bio files for $75M mixed shelf
https://seekingalpha.com/news/4104887-gri-bio-files-for-75m-mixed-shelf?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
May 10, 2024 - GRI Bio files a prospectus for a mixed shelf offering of up to $75M.
0
Entera Bio GAAP EPS of -$0.05 beats by $0.01
https://seekingalpha.com/news/4104855-entera-bio-gaap-eps-of-0_05-beats-0_01?source=feed_tag_israel
May 10, 2024 - Entera Bio (ENTX) reports Q1 2024 financial results, beating expectations with a GAAP EPS of -$0.05, exceeding estimates by $0.01.
0
Kronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2271793/kronos-bio-inc-kron-reports-q1-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2271793
May 09, 2024 - Kronos Bio (KRON) delivered earnings and revenue surprises of -16.28% and 68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
0
Annovis Bio to post late-stage data for Parkinson's drug in June
https://seekingalpha.com/news/4104001-annovis-bio-stock-gains-plans-parkinsons-readout?source=feed_sector_healthcare
May 09, 2024 - Annovis Bio (ANVS) stock gains on plans to share Phase 3 data for its lead candidate buntanetap in early Parkinson's disease in June. Read more here.
0